Organovo. has filed a patent for compounds that act as farnesoid X receptor agonists. The patent includes methods of making these compounds, pharmaceutical compositions, and their use in treating conditions related to farnesoid X receptor activity. GlobalData’s report on Organovo gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Organovo, 3D Bioprinting was a key innovation area identified from patents. Organovo's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.
A patent application (Publication Number: US20230382913A1) discloses a series of compounds and pharmaceutical compositions for treating liver diseases, liver fibrosis, liver inflammation, gastrointestinal diseases, and conditions that would benefit from treatment with an FXR agonist. The compounds are represented by specific chemical formulas and structures, with variations in substituents and functional groups. The patent claims cover the compounds, their pharmaceutically acceptable salts or solvates, and their use in treating various liver and gastrointestinal conditions.
The disclosed compounds can be administered in various forms, including tablets, capsules, liquids, gels, and ointments, for intravenous, subcutaneous, oral, inhalation, nasal, dermal, or ophthalmic administration. The methods outlined in the patent application involve administering the compounds to mammals to treat or prevent liver diseases such as alcoholic or non-alcoholic liver disease, liver fibrosis, liver inflammation, and gastrointestinal diseases like ulcerative colitis, Crohn's disease, and irritable bowel syndrome. The compounds act as FXR agonists and can be used alone or in combination with other therapeutic agents for enhanced efficacy in treating the specified conditions. The patent application provides a detailed description of the chemical structures, formulations, and methods of administration for these novel compounds, highlighting their potential in addressing a range of liver and gastrointestinal disorders.
To know more about GlobalData’s detailed insights on Organovo, buy the report here.
See Also:
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
